Study of GB18 Injection for Cancer-Related Weight Loss
Part of Cancer clinical trials.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer (not removable by surgery) that has spread or come back, and standard treatments haven't worked or aren't available
- You have experienced significant unintended weight loss or have a low body mass index due to your cancer
- Your blood work shows specific levels of a protein called GDF15 and normal kidney, liver, and blood cell counts
- Your heart pumps blood effectively (ejection fraction greater than 50%) and you're in reasonable overall health
- You haven't had recent heart problems, strokes, blood clots, or major surgery in the past month
- You're not currently on tube feeding, IV nutrition, or recently started steroid medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called postbiotics (which are helpful byproducts from good bacteria) to see if they can help reduce weight loss and muscle wasting in people with advanced lung cancer. If you have this type of cancer and have been losing weight, this study might offer a way to help you feel stronger and improve your quality of life.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
This trial tests whether transplanting healthy gut bacteria (called a fecal microbiota transplant, or FMT) can help people with advanced cancer who are losing weight and muscle. The goal is to see if it improves appetite and helps you maintain strength.
This early-phase trial tests a new injection called GB18 in healthy adults to see if it is safe and how the body processes it. It may help researchers understand how to treat conditions that involve the immune system.
This trial tests an investigational injection called INB301 to see if it can help reduce weight loss and improve appetite in people with cancer-related wasting (cachexia). It is a phase 1/2 study, so it is one of the first times the drug is given to people, and safety is a key goal.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
Hear when a new Cachexia; Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.